Pada kesempatan kali ini saya akan membahas mengenai penanganan penyakit eritroblastosis fetalis. Sebelumnya , pernah dengar tidak tentang penyakit ini? Istilah eritroblastosis mungkin cukup asing di telinga pembaca, tapi mari kita pahami satu per satu. Eritroblastosis berasal dari kata eritrosit yaitu sel darah merah dan juga fetalis atau fetal yaitu berarti janin atau bayi. Dari dua kata tersebut, kita bisa tahu bahwa eritroblastosis fetalis adalah penyakit kelainan sel darah merah pada janin.
|Genre:||Health and Food|
|Published (Last):||12 October 2012|
|PDF File Size:||8.58 Mb|
|ePub File Size:||11.77 Mb|
|Price:||Free* [*Free Regsitration Required]|
Share on Pinterest The newborn may need urgent medical treatment. Treatment may include a fetal blood transfusion and delivery of the fetus between 32 and 37 weeks gestation. Treatment options for newborns with the condition include: blood transfusion managing breathing problems IV immunoglobulin IVIG The goal of IVIG antibody therapy is to reduce the breakdown of red blood cells and levels of circulating bilirubin.
Sometimes, an exchange transfusion is necessary. This type of transfusion involves replacing small amounts of blood with different blood. The goal is to increase the presence and number of red blood cells and to lower bilirubin levels.
Prevention Erythroblastosis fetalis is a preventable condition. This medication prevents the pregnant woman from developing Rh-positive antibodies.
However, this will not help women who have already undergone Rh sensitization. Women at risk for Rh sensitization should receive RhoGAM doses at specific times during their pregnancy and after delivery. These include: at 28 weeks of gestation 72 hours following delivery, if the newborn is Rh-positive within 72 hours of a miscarriage, abortion, or ectopic pregnancy following an invasive prenatal test, such as an amniocentesis or CVS after any vaginal bleeding If a woman has a pregnancy that extends beyond 40 weeks, the doctor may recommend an additional dose of RhoGAM.
Erythroblastosis fetalis is a potentially dangerous condition that occurs during the development of an infant. The condition occurs when a component of blood called Rh factor is incompatible between the pregnant woman and the fetus. It can cause jaundice and other, more severe complications, including possible heart failure. Treatment includes blood transfusion, IV fluids, immunoglobin, and addressing any breathing difficulties. Giving a pregnant woman Rh immunoglobin can also help prevent the condition by blocking Rh sensitization.
Q: Does this condition have any long-term effects on a newborn? A: If a fetus with erythroblastosis fetalis survives and is born alive, the infant may be extremely ill. The lack of oxygen caused by severe anemia around the time of birth can lead to long-term damage to the brain and other organs. Kernicterus caused by high bilirubin levels can also cause permanent brain damage. However, erythroblastosis fetalis is preventable, and these complications are rare. Karen Gill, MD Answers represent the opinions of our medical experts.
All content is strictly informational and should not be considered medical advice.
Share on Pinterest The newborn may need urgent medical treatment. Treatment may include a fetal blood transfusion and delivery of the fetus between 32 and 37 weeks gestation. Treatment options for newborns with the condition include: blood transfusion managing breathing problems IV immunoglobulin IVIG The goal of IVIG antibody therapy is to reduce the breakdown of red blood cells and levels of circulating bilirubin. Sometimes, an exchange transfusion is necessary. This type of transfusion involves replacing small amounts of blood with different blood.
Can persist up to 12 weeks after birth. If a mother is exposed to a foreign antigen and produces IgG as opposed to IgM which does not cross the placenta , the IgG will target the antigen, if present in the fetus, and may affect it in utero and persist after delivery. The three most common models in which a woman becomes sensitized toward i. Fetal-maternal hemorrhage , which is the movement of fetal blood cells across the placenta, can occur during abortion , ectopic pregnancy , childbirth , ruptures in the placenta during pregnancy often caused by trauma , or medical procedures carried out during pregnancy that breach the uterine wall. In subsequent pregnancies, if there is a similar incompatibility in the fetus, these antibodies are then able to cross the placenta into the fetal bloodstream to attach to the red blood cells and cause their destruction hemolysis. ABO blood group system and the D antigen of the Rhesus Rh blood group system typing are routine prior to transfusion.
Hemolytic disease of the newborn